Breaking Finance News

Bayer (ETR:BAYN) price target upped to 103.00EUR, released a report earlier today by Bankhaus Lampe KG

Just yesterday Bayer (ETR:BAYN) traded 0.00% even at 89.15EUR. Bayer’s 50-day moving average is 0.04EUR and its two hundred day average is 0.03EUR. With the last close up -4.07% relative to the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same time. 0 shares of the stock were exchanged, down from an avg. volume of 215

In a report issued 9/29/2016 Bankhaus Lampe KG bumped up the target of Bayer (ETR:BAYN) to 103.00EUR indicating a possible upside of 0.16%.

On 9/28/2016, Bankhaus Lampe KG released a statement about Bayer (ETR:BAYN) upped the target price from 0.00EUR to 103.00EUR that suggested an upside of 0.16%.

Performance Chart

Bayer (ETR:BAYN)

Bayer has 52 week low of 0.03EUR and a 52 week high of 0.04EUR and has a total market value of 0 EUR.

General Company Details For Bayer (ETR:BAYN)

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures. The Consumer Health segment is engaged in the development of over-the-counter medications, dermatology products and nutritional supplements. The Crop Science segment is engaged in the development of product portfolio in the areas of seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural pest control. The Animal Health segment is engaged in the development of veterinary medicines and animal grooming products. Covestro is engaged in the development of raw materials for polyurethanes; polycarbonate resins and sheets; raw materials for coatings, adhesives and sealants; and selected chemical intermediates.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *